> Shares of Cadence Pharmaceuticals soared 59 percent on the news that its painkiller Acetavance met its primary goal in a late-stage trial. The primary endpoint was a statistically significant reduction in summed pain intensity differences from baseline over 24 hours for Acetavance 1000 mg compared to placebo. Report
> Bristol-Myers Squibb will be handing layoff notices to another 10 percent of its 37,000 remaining workers, likely due to weak pipelines, increasing regulatory burdens, looming generic competition and (do we even need to say it?) the economy. Report
> Portuguese contract manufacturer Hovione has purchased Pfizer's Cork, Ireland facility for an undisclosed sum. Report
> There is not a large enough supply of a major colorectal cancer chemotherapy medication, Forbes reports today. Report
> Amgen whistleblower Darrell G. Dotson, of Newbury Park, will have his day in court and bypass Amgen's arbitration process, ruled Ventura County Superior Court judge, Henry Walsh. Report
> Ovation Pharmaceuticals may be in hot water. The company purchased the rights to Merck's Indocin in 2005, bought a rival drug in 2006 and then hiked the prices of both, according to allegations made by the Federal Trade Commission. Report
> Prosensa Holding has closed an 18 million euro Series B round. Gimv (Antwerp) and AGF (Paris) joined current shareholders LSP, Abingworth and MedSciences Capital in the round. Release
> Crucell has signed a second licensing deal with Talecris Biotherapeutics for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6 cell line. Release
> NicOx announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis from the 301, 302 and 303 pivotal Phase III studies for naproxcinod. Release
> Belgium's Devgen has reached a deal with the trade unions to close its pharma division, a move that will lead to the termination of 19 workers. Report
> Addex Pharmaceuticals has launched a Phase IIb trial of ADX10059 as a migraine prevention therapy in people who suffer from 3 or more migraine attacks per month. Release
And Finally... The FDA is requiring warnings on a laundry list of antiepileptic medications that say that use of the drugs increases the risk of suicidal thoughts and behaviors. Report